Payment overview · 2025
General Payments
$327.81
18 reported records · 5 companies
Healthcare provider profile · identity verified
Glennette Haney, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ALTON, MO · NPI 1003967951
Verified facts
What the public records show
CMS Open Payments records show Glennette Haney, APRN received $327.81 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.02 | 49.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.63 | 15.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.95 | 14.9% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $41.24 | 12.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.97 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.81 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.30 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.63 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.63 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.95 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 352 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 228 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
352 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 840 | 129 |
| Furosemide | Furosemide | 751 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 725 | 121 |
| Lisinopril | Lisinopril | 661 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 618 | 100 |
| Valsartan | Valsartan | 576 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 515 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 510 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 77 |
| Famotidine | Famotidine | 468 | 73 |
| Gabapentin | Gabapentin | 422 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 383 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 376 | 69 |
| Potassium Chloride | Potassium Chloride | 372 | 65 |
| Fenofibrate | Fenofibrate Nanocrystallized | 354 | 54 |
| Farxiga | Dapagliflozin Propanediol | 352 | 47 |
| Losartan Potassium | Losartan Potassium | 321 | 54 |
| Metformin Hcl Er | Metformin Hcl | 304 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 301 | 55 |
| Montelukast Sodium | Montelukast Sodium | 299 | 51 |
| Tramadol Hcl | Tramadol Hcl | 265 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 264 | 48 |
| Sertraline Hcl | Sertraline Hcl | 261 | 46 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 256 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 246 | 35 |
| Trazodone Hcl | Trazodone Hcl | 246 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 244 | 54 |
| Ozempic | Semaglutide | 228 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 215 | 31 |
| Zonisamide | Zonisamide | 213 | 38 |
| Sucralfate | Sucralfate | 199 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 196 | 25 |
| Meloxicam | Meloxicam | 191 | 32 |
| Entresto | Sacubitril/Valsartan | 174 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 174 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 170 | 26 |
| Propranolol Hcl | Propranolol Hcl | 166 | 26 |
| Glipizide Er | Glipizide | 162 | 24 |
| Mounjaro | Tirzepatide | 153 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 40 |
| Allopurinol | Allopurinol | 149 | 25 |
| Omeprazole | Omeprazole | 142 | 23 |
| Acarbose | Acarbose | 138 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 24 |
| Carvedilol | Carvedilol | 121 | 20 |
| Vascepa | Icosapent Ethyl | 121 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 120 | 16 |
| Doxepin Hcl | Doxepin Hcl | 117 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 115 | 18 |
| Mirtazapine | Mirtazapine | 115 | 21 |
| Eliquis | Apixaban | 114 | 19 |
| Lovastatin | Lovastatin | 113 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 108 | 22 |
| Buspirone Hcl | Buspirone Hcl | 107 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 107 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 106 | 15 |
| Jardiance | Empagliflozin | 103 | 21 |
| Finasteride | Finasteride | 100 | 23 |
| Metformin Hcl | Metformin Hcl | 100 | 16 |
| Alendronate Sodium | Alendronate Sodium | 94 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 18 |
| Topiramate | Topiramate | 91 | 19 |
| Aripiprazole | Aripiprazole | 88 | 11 |
| Xarelto | Rivaroxaban | 88 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 86 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 86 | 20 |
| Donepezil Hcl | Donepezil Hcl | 82 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 79 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | suppressed |
| Spironolactone | Spironolactone | 77 | 19 |
| Repatha Sureclick | Evolocumab | 75 | 13 |
| Rybelsus | Semaglutide | 71 | 22 |
| Simvastatin | Simvastatin | 71 | suppressed |
| Bupropion Xl | Bupropion Hcl | 70 | 14 |
| Celecoxib | Celecoxib | 65 | 15 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 18 |
| Atenolol | Atenolol | 61 | suppressed |
| Baclofen | Baclofen | 61 | suppressed |
| Nystatin | Nystatin | 60 | 25 |
| Liothyronine Sodium | Liothyronine Sodium | 59 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | suppressed |
| Estradiol | Estradiol | 56 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Pregabalin | Pregabalin | 53 | 13 |
| Nifedipine Er | Nifedipine | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Linzess | Linaclotide | 47 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Olanzapine | Olanzapine | 46 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 44 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Prednisone | Prednisone | 42 | 28 |
| Torsemide | Torsemide | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 38 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 23 |
| Levemir Flexpen | Insulin Detemir | 37 | 13 |
| Mupirocin | Mupirocin | 37 | 29 |
| Armour Thyroid | Thyroid,pork | 34 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Praluent Pen | Alirocumab | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Roflumilast | Roflumilast | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Techlite Pen Needle | Pen Needle, Diabetic | 30 | 16 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 22 |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 11 |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | 12 |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.81 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, OTEZLA, Ozempic, REPATHA, Rybelsus, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error